Clinical trial

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT05208762

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2022-10-25

PhasePHASE1

Study timeline

Study start (actual)2022-10-25Date precision: day

Registry last updated2026-07-22

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Carcinoma, Non-Small-Cell Lungunresolved

Squamous Cell Carcinoma of the Head and Neckunresolved

Esophageal Squamous Cell Carcinomaunresolved

Triple Negative Breast Neoplasmsunresolved

Gastric Cancerunresolved

Endometrial Cancerunresolved

Pancreatic Adenocarcinomaunresolved

Hepatocellular Carcinomaunresolved

Interventions

PF-08046054DRUG

pembrolizumabDRUG · verified · RxNorm: pembrolizumab

Sponsors & collaborators

Seagen, a wholly owned subsidiary of Pfizerlead sponsor

Mapped research locations

DallasTexas, United States5 BirminghamAlabama, United States4 BarcelonaSpain3 LondonUnited Kingdom3 BerlinGermany3 HoustonTexas, United States2 TorontoOntario, Canada2 San AntonioTexas, United States2 ParisFrance2 BeijingBeijing Municipality, China2 SacramentoCalifornia, United States2 VillejuifFrance2

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT05208762 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.